SCHEMBL18558208

SCHEMBL18558208

Cc1ccc(-c2cc(N/C(=N\C(=O)c3ccc(F)c(F)c3)NCc3ccc(F)cc3Cl)[nH]n2)cc1F

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 14/20 0.41
ROCK2 O75116 3/20 0.41
ROCK1 Q13464 3/20 0.41
CYP3A4 P08684 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC11 Q96DB2 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC9 Q9UKV0 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
NCOR2 Q9Y618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18558559 0.92 P2RX7 (0.42) P2RX7ROCK2ROCK1HDAC3HDAC4
SCHEMBL18558655 0.92 HDAC3 (0.43) P2RX7ROCK2ROCK1HDAC3HDAC4
SCHEMBL18558406 0.91 HDAC3 (0.41) P2RX7ROCK2ROCK1HDAC3HDAC4
SCHEMBL18558638 0.90 P2RX7 (0.42) P2RX7ROCK2ROCK1HDAC3HDAC4
SCHEMBL18558236 0.88 TP53 (0.45) P2RX7ROCK2ROCK1HDAC3HDAC4
SCHEMBL18558567 0.88 MAPT (0.45) P2RX7ROCK2ROCK1HDAC3HDAC4
SCHEMBL17088577 0.87 P2RX7 (0.46) P2RX7ROCK2ROCK1
SCHEMBL19362641 0.87 P2RX7 (0.42) P2RX7ROCK2ROCK1HDAC3HDAC4
SCHEMBL18558275 0.87 HDAC3 (0.43) P2RX7ROCK2ROCK1HDAC3HDAC4
SCHEMBL19362718 0.85 HDAC3 (0.47) P2RX7ROCK2ROCK1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9932313-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2018-04-03 US disclosed
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-09-21 US disclosed
US-9580388-B2 Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2017-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267643-A1 PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF ATP5F1A, ATP5F1D, ATP5ME P2RX7 93/4885ROCK2 1467/4885ROCK1 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.